Experimental justification of the possibility of creating the new metabolic drug
- Authors: Zabokritsky N..1, Sarapultsev P..1
-
Affiliations:
- Federal State Budgetary Scientifi c Institution Research Institute of Immunology and Physiology of the Ural Branch of the Russian Academy of Sciences
- Issue: Vol 21, No 3 (2018)
- Pages: 295-300
- Section: ORIGINAL ARTICLES
- URL: https://ogarev-online.ru/1028-7221/article/view/119861
- DOI: https://doi.org/10.31857/S102872210002398-2
- ID: 119861
Cite item
Full Text
Abstract
This scientifi c work is devoted to the study of the possibility of creating a new metabolic drug (using biologically active substances of the probiotic strain Bacillus subtilis B-3679) for use as a preventive and therapeutic agent for infl ammatory diseases of tissues and organs of the oral cavity. Previously, the metabolites of spore probiotic microorganisms were practically not used for the design of medical pharmacological preparations.
About the authors
N. . Zabokritsky
Federal State Budgetary Scientifi c Institution Research Institute of Immunology and Physiology of the Ural Branch of the Russian Academy of Sciences
Author for correspondence.
Email: noemail@neicon.ru
Russian Federation
P. . Sarapultsev
Federal State Budgetary Scientifi c Institution Research Institute of Immunology and Physiology of the Ural Branch of the Russian Academy of Sciences
Email: noemail@neicon.ru
Russian Federation
References
- Забокрицкий Н. А. Экспериментальная оценка коррекции гуморального иммунитета гепатопротекторным препаратом гепатобиол у лабораторных животных с острым токсическим гепатитом. Российский иммунологический журнал, 2017, 11, 2(20), 123–126. [Zabokritskiy N. A. Experimental estimation of correction of humoral immunity hepatoprotective drug hepatobiol in laboratory animals C acute toxic hepatitis, 2017, 11, 2(20), 123–126].
- Забокрицкий Н. А. Оценка иммунотропного действия пробиотика бацилакт в составе трансдермальных терапевтических систем. Российский иммунологический журнал, 2017, 11, 2(20), 126–129. [Zabokritskiy N. A. Preclinical evaluation of immunotropic action of probiotics bacilack transdermal therapeutic system, 2017, 11, 2(20), 126–129].
- Забокрицкий Н. А. Обоснование направлений в разработке и экспериментальном изучении новых фармакологических препаратов на основе пробиотиков и их биологически активных продуктов: автореф. дис. … д-ра. мед. наук., 2014. 3–16. [Zabokritskiy N. A. Study areas in the development and experimental study of new pharmacological products based on probiotics and their bioactive products: abstract of dis. … dr. med. sciences, 2014. 3–16].
- Лабинская А. С. Микробиология с техникой микробиологических исследований. Бином, М., 2012. 72–124. [Labinskaya А. S. Microbiology with technique of microbiological studies.: Binom, Moscow, 2012. 72–124].
- Holzapfel W. H., Schillinger U. Introduction to preand probiotics. Food Research International 35, 2002, 109–116.
- Kailasapathy K. A., Chin J. Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifi dobacterium spp. Immunol. Cell. Biol., 2000, 78, 80–88.
- Lee Y. K., Salminen S. Handbook of Probiotics and Prebiotics. John Wiley and Sons, Ltd., 2009, 132–144.
- Russel J., Cohn R.,Probiotics. U.K., Edinburgh: LENNEX Corp. 2012, 5–58.
Supplementary files
